Paul Badawi Biography and Net Worth

Prior to launching Sight Sciences, Paul led the U.S. healthcare venture capital practice for 3i Group, a global private equity firm.

At 3i, Paul managed a portfolio of early, mid, and late stage private medical device investments. He served as a lead investor and board member for Ulthera (acquired by Merz), Xthetix (acquired by J&J), NeoGuide (acquired by Intuitive Surgical), OmniGuide, and Sotera Wireless, and as an observer on the boards of Small Bone Innovations (acquired by Stryker), Zonare (acquired by Mindray), and Transmedics. Prior to entering the medical device world, Paul worked at the National Institutes of Health as a Research Fellow in the biochemical genetics laboratory of a Nobel Prize-winning scientist credited with cracking the genetic code. Paul received a BS in Biological Sciences from the University of Chicago, an MBA from UCLA, and is a graduate of the Kauffman Fellows Program.

What is Paul Badawi's net worth?

The estimated net worth of Paul Badawi is at least $32.61 million as of April 1st, 2026. Mr. Badawi owns 6,151,156 shares of Sight Sciences stock worth more than $32,607,278 as of May 7th. This net worth evaluation does not reflect any other assets that Mr. Badawi may own. Learn More about Paul Badawi's net worth.

How do I contact Paul Badawi?

The corporate mailing address for Mr. Badawi and other Sight Sciences executives is 4040 CAMPBELL AVE SUITE 100, MENLO PARK CA, 94025. Sight Sciences can also be reached via phone at 877-266-1144 and via email at [email protected]. Learn More on Paul Badawi's contact information.

Has Paul Badawi been buying or selling shares of Sight Sciences?

In the last ninety days, Paul Badawi has sold $108,202.80 in shares of Sight Sciences stock. Most recently, Paul Badawi sold 29,244 shares of the business's stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $3.70, for a transaction totalling $108,202.80. Following the completion of the sale, the chief executive officer now directly owns 6,151,156 shares of the company's stock, valued at $22,759,277.20. Learn More on Paul Badawi's trading history.

Who are Sight Sciences' active insiders?

Sight Sciences' insider roster includes David Badawi (Founder & Chief Technology Officer), Paul Badawi (Founder & Chief Executive Officer), Alison Bauerlein (CFO), Staffan Encrantz (Director), Jeremy Hayden (Chief Legal Officer), James Rodberg (CFO), Jesse Selnick (CFO), and Brenton Taylor (Executive Vice President, Operations and R&D). Learn More on Sight Sciences' active insiders.

Are insiders buying or selling shares of Sight Sciences?

In the last year, insiders at the sold shares 30 times. They sold a total of 307,648 shares worth more than $1,746,086.49. The most recent insider tranaction occured on April, 6th when CFO James Rodberg sold 7,231 shares worth more than $25,670.05. Insiders at Sight Sciences own 30.9% of the company. Learn More about insider trades at Sight Sciences.

Information on this page was last updated on 4/6/2026.